These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 27701365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H, Iwai M, Taniuchi Y, Katashima M, Takahashi H.
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S.
    J Inherit Metab Dis; 1996 Dec; 19(2):234-8. PubMed ID: 8739974
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J, Vilaseca Buscà MA, Lambruschini Ferri N, Mas Comas A, González Pascual E, Holme E.
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [Abstract] [Full Text] [Related]

  • 15. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A, Rózsa M, Sallay E, Tiszlavicz L, Janovszky A, Várkonyi A, Karg E, Wittmann G, Túri S, Ugarte M.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):415-9. PubMed ID: 24555242
    [Abstract] [Full Text] [Related]

  • 16. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
    Bendadi F, de Koning TJ, Visser G, Prinsen HC, de Sain MG, Verhoeven-Duif N, Sinnema G, van Spronsen FJ, van Hasselt PM.
    J Pediatr; 2014 Feb 30; 164(2):398-401. PubMed ID: 24238861
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nontransplant treatment of tyrosinemia.
    Holme E, Lindstedt S.
    Clin Liver Dis; 2000 Nov 30; 4(4):805-14. PubMed ID: 11232358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.